Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Facon, Thierry, Kumar, Shaji, Plesner, Torben, Orlowski, Robert Z., Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth, Hulin, Cyrille, Quach, Hang, Goldschmidt, Hartmut, O’Dwyer, Michael, Perrot, Aurore, Venner, Christopher P., Weisel, Katja, Mace, Joseph R., Raje, Noopur, Attal, Michel, Tiab, Mourad, Macro, Margaret, Frenzel, Laurent, Leleu, Xavier, Ahmadi, Tahamtan, Chiu, Christopher, Wang, Jianping, Van Rampelbergh, Rian, Uhlar, Clarissa M., Kobos, Rachel, Qi, Ming, Usmani, Saad Z.·2019·New England Journal of Medicine
DOI 10.1056/nejmoa1817249

Cited by (1,013)

Items 901–1,000 of 1,013

  1. Establishing Measurable Residual Disease Trajectories for Patients on Treatment for Newly Diagnosed Multiple Myeloma as Benchmark for Deployment of T-cell Redirection Therapy
    Susan Bal, Tylan Magnusson, Gayathri Ravi et al. · 2024 · Research Square
  2. DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma
    Anupama Deepa Kumar, Alfred Chung, Darren Pan, Ajai Chari · 2024 · The Hematologist
  3. Value-based pharmaceutical care at population, hospital and patient level
    Job F. H. Eijsink · 2024 · University of Groningen research database (University of Groningen / Centre for Information Technology)
  4. Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era
    Vânia Hungria, Jorge Vaz Pinto Neto, Pedro Manoel Marques Garibaldi, Angela Marie Jansen, Roberto Josè Pessoa de Magalhães Filho, Fernando Vieira Pericole, Gayatri Sanku, Ângelo Maiolino · 2024 · Clinical Lymphoma Myeloma & Leukemia
  5. Plasma Cell Disorders
    Alexis K. Williams, Kimberley Doucette · 2024 · Springer eBooks
  6. The lifecycle and evolution of new regimens on the National Comprehensive Cancer Network Guidelines for newly diagnosed multiple myeloma
    Ghulam Rehman Mohyuddin, Jehad Almasri, Aaron Michael Goodman, Alyson Haslam, Vinay K. Prasad · 2024 · The Oncologist
  7. Immuntherapien des multiplen Myeloms
    Sofie‐Katrin Kadel, Leo Rasche · 2025 · Die Onkologie
  8. 10.1016/s1155-1984(23)47566-8
    2000 · Time to knit
  9. Myélome multiple : ce que le rhumatologue doit savoir en 2025
    Rakiba Belkhir · 2025 · Revue du Rhumatisme
  10. Optimising quadruplet regimens to broaden eligibility in multiple myeloma
    Tanya Marya Wildes · 2025 · The Lancet Haematology
  11. Phase 2 trial of daratumumab, cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma
    Edvan de Queiroz Crusoé, Joanna Suzana Leal Ribeiro dos Santos, Juliana de Andrade Santos et al. · 2025 · Blood Neoplasia
  12. Multiple myeloma
    Karthik Ramasamy, Sagar Lonial · 2025 · Wiley eBooks
  13. Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy
    Susan Bal, Tylan Magnusson, Gayathri Ravi, Smith Giri, Kelly Nicole Godby, Binod Dhakal, Natalie S. Callander, Rebecca Wang Silbermann, Bhagirathbhai Dholaria, Vishnu Reddy et al. · 2025 · Blood Cancer Journal
  14. Myélome et risque infectieux : quel rôle pour l’infirmière en pratique avancée ?
    Margot Brossard, Marion Gire, Stéphanie Malartre-Sapienza · 2025 · Soins
  15. MLN0905, a new inhibitor of Polo-like kinase 1 (PLK1), enhances the efficiency of lenalidomide in promoting the apoptosis of multiple myeloma cell lines
    Reyhane Piri, Minoo Shahidi, Zahra Pooraskari · 2025 · Investigational New Drugs
  16. T cell phenotype and clonality changes in myeloma patients with short overall survival
    Alenka Djarmila Behsen, Esten N. Vandsemb, Tobias Schmidt Slørdahl, Karen Dybkær, Maja Zimmer Jakobsen, Muhammad Kashif, Johan Lund, Vincent Luong, Astrid Marta Olsnes, Anders Waage et al. · 2025 · JCI Insight
  17. Role of NK Cells in Progression and Treatment of Multiple Myeloma
    Iman Chanchiri, Emil Birch Christensen, Niels Abildgaard, Torben Barington, Thomas Lund, Jakub Krejcik · 2025 · Frontiers in Bioscience-Landmark
  18. Temporal Trends in Multiple Myeloma Mortality and Their Relationship to Evolving Treatment Strategies: A Retrospective Analysis Using SEER Data
    Navkirat Kahlon · 2025 · Research Square
  19. Hilfe bei der Wahl der bestmöglichen Erstlinientherapie
    Luisa Mertens, Marcus Hentrich, Marion Högner · 2025 · InFo Hämatologie + Onkologie
  20. Potential surrogate endpoint for B-cell hematologic malignancy: A systematic review and meta-analysis
    Satoshi Hirano, Keisuke Hanada, Hideki Maeda · 2025 · Scientific Reports
  21. Plasma cell disorders
    Caitlin L. Costello, Rafaël Fonseca · 2022
  22. Plasma cell disorders: monoclonal gammopathy of undetermined significance and multiple myeloma
    Caitlin L. Costello · 2025
  23. Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma
    Matthew James Pianko, Niodita Gupta‐Werner, Bruno Émond, Patrick Lefèbvre, Marie-Hélène Lafeuille, Annelore Cortoos, Shuchita Kaila · 2025 · Future Science OA
  24. Meta-analysis of the prognostic efficacy of daratumumab combined with standard therapy in high-risk multiple myeloma
    Hongmei Zhou, Min Zhang, Yi Jin, Xianghua Lang · 2025 · Hematology
  25. Daratumumab (Darzalex SC)
    CDA-AMC · 2025 · Canadian Journal of Health Technologies
  26. Use of CD38 Antibodies in High-Risk Newly Diagnosed Multiple Myeloma: A Meta-Analysis
    Divaya Bhutani, Yusha Katie Liu, Rajshekhar Chakraborty, Michael Sang Hughes, Suzanne Lentzsch, Samuel M. Rubinstein · 2026 · Clinical Lymphoma Myeloma & Leukemia
  27. Perspectives on Newly Diagnosed Myeloma Treatment and Emerging Challenges
    Cyrille Touzeau, Philippe Moreau · 2025 · Blood Cancer Discovery
  28. Das Multiple Myelom im Detail
    Francesca Gay, Edoardo Marchetti, Giuseppe Bertuglia · 2025 · Kompass Onkologie
  29. Newly Diagnosed High‐Risk Multiple Myeloma: Outcomes and Management
    Fatma Zehra Yasar, Elan Gorshein · 2025 · Advances in Hematology
  30. Immunotherapy for Multiple Myeloma
    Anthony A. Oyekunle · 2025 · Springer eBooks
  31. New Zealand Multiple Myeloma Patients Demonstrate Inferior Outcomes When Compared to Australian Counterparts – A Retrospective Cohort Study from the Myeloma and Related Diseases Registry (MRDR)
    Jian Li, Yayehirad Alemu Melsew, Cameron J. Wellard et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
  32. Targeting Wnt/β-catenin signaling enhances the efficacy of anti-CD38 immunotherapy in multiple myeloma
    Heng Li, Yunguang Chen, Michaela Gregorová, Tingting Yang, Xiayi Zhang, Xiaoyu Yu, Zhen Wang, Haiying Hua, Long Ye, Xiaowei Qi et al. · 2025 · Neoplasia
  33. Developing antisense therapeutics for multiple myeloma
    Alexander Kapphahn, Nikki Truong, Mahnoor Khan, Annaliza Ashitey, Dominic Alfano, Anisha Gupta · 2025 · Cell Reports Physical Science
  34. Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan
    Kazuhito Suzuki, Miku Ito, Chika Sakai, Hiroaki Tsuchiya, David Bin‐Chia Wu, Yosuke Koroki · 2025 · Current Medical Research and Opinion
  35. Effective front-line treatment of osteosclerotic myeloma with POEMS syndrome with daratumumab, lenalidomide and dexamethasone: a case report and literature review
    Chiel Gharakhani, Alexander Soetens, Wouter C. J. Huysse · 2025 · Acta Clinica Belgica
  36. The efficacy and safety of anti-CD38 monoclonal antibodies in transplant-ineligible newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials
    Turkan Aliyeva, Haroon Alamy, Feras Ahmad Ibrahim Ahmad, Julia Natche, Hafiz Shah, Vrushali Shelar, Huu Than Huynh, Imane El Amri · 2025 · Current Research in Translational Medicine
  37. Gain/Amplification 17p as a Potential Favorable Prognostic Factor in Multiple Myeloma: A Real‐World Settings Retrospective Study
    Teng Wang, Siyuan Cui, Jingyi Wang, Zhaoxia Liu, Kui Liu, Zhenzhen Wang, Xinyu Thomas Tang, Liu D, Yan Wang, Ruirong Xu · 2025 · eJHaem
  38. Daratumumab bortezomib and dexamethasone in transplant ineligible newly diagnosed elderly myeloma patients (AMN006)—a trial by Asian Myeloma Network (NCT03695744)
    Melinda Si Yun Tan, Chandramouli Nagarajan, Melissa Gaik Ming Ooi, Sanjay De Mel, Nur Shahidah Binte Hashim, Xinhua Li, Ashlett Chua, Yogesh Mahadev Pokharkar, Allison Ching Yee Tso, Neha Awasthi et al. · 2025 · Leukemia & lymphoma/Leukemia and lymphoma
  39. Isatuximab, bortezomib, lénalidomide et dexaméthasone – myélome multiple nouvellement diagnostiqué inéligible à la greffe
    Aurélien Pichon, Arthur Bobin · 2025 · Bulletin du Cancer
  40. The Improvement of Treatment Outcomes in Multiple Myeloma Patients Non-Eligible for HDCT and Auto-HSCT Using New Approaches to Early Lines of Therapy (Meeting of Expert Panel)
    2020 · Clinical oncohematology
  41. An atypical POEMS-like paraneoplastic syndrome associated with IgA κ smoldering multiple myeloma treated with daratumumab
    Tanushree Bhatt, Bhuwan Bhatta, Alexander Johnston · 2026 · Current Problems in Cancer Case Reports
  42. Multiple myeloma in the real world settings: prognostic significance of 1q21 chromosomal abnormalities - single center experience
    Aleksandra Sretenović, Marko Mitrovic, Zoran Bukumirić, Nikola Vukosavljevic, Natalija Kecman, Jelica Jovanović, Marija Dencic Fekete, Enisa Zaric, Jelena Bila · 2026 · Frontiers in Oncology
  43. Treatment with Daratumumab in Combination with Glucocorticosteroids as First-Line Treatment Achieves a Complete Remission for a Patient with Multiple Myeloma and Resolves Neutropenia: A Case Report
    Sarah Mettias, Jamie Cheung, Jonathan Moore, James R. Berenson · 2026 · Case Reports in Oncology
  44. Advancing multiple myeloma therapy: A systematic analysis of corticosteroids and monoclonal antibodies as dual therapeutic agents
    Farah Alam, Huma Siddiqui, Arpna Nihal, Madiha Andleeb, Amna Qamar uz Zaman, Mehwish Imam Khushk, Fatima Hussain, Rahul Rai, Fasiha Fatima, Danaish Kumar et al. · 2026 · World Journal of Methodology
  45. Clinical factors associated with venous thromboembolism in multiple myeloma patients treated with daratumumab
    Naveen G. Subramanian, Fleur M. Aung, Zachary Hunzeker, Krina K. Patel, Hans Chulhee Lee, Shida Jin, Elliana J. Young, Roland L. Bassett, Cristhiam Mauricio Rojas Hernandez · 2026 · Discover Medicine
  46. Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated With Front‐Line Daratumumab Lenalidomide and Dexamethasone
    Ricardo Daniel Parrondo, Ricardo C. B. de Menezes, Hanna J. Sledge, Madhavi Nayyar, Kanika Yadav, Peter Leif Bergsagel, Rafaël Fonseca, Prashant Kapoor, Francis K. Buadi, Morie Abraham Gertz et al. · 2026 · American Journal of Hematology
  47. 2. Update on multiple myeloma -including related diseases-
    Tadao Ishida · 2025 · Nihon Naika Gakkai Zasshi
  48. Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report
    Martha Louzada, Donna Ellen Reece, Christopher Paul Venner, Darrell J. White, Jiandong Su, Michael Patvin Chu, Victor H. Jimenez- Zepeda, Arleigh B. Robertson McCurdy, Kevin Song, Hira S. Mian et al. · 2026 · Blood Neoplasia
  49. Genomic profiling enables personalized strategies to overcome drug resistance in multiple myeloma
    Fengbo Zeng, Azin Taki · 2026 · Discover Oncology
  50. Role of Radiotherapy in the Era of Novel Immune‐Based Treatment Strategies for Multiple Myeloma
    Tom Schlusemann, Evgenii Shumilov, Gabriele Reinartz, David Rene Steike, Sebastian Lohmann, Stefan Gravemeyer, Matthias Stelljes, Georg Lenz, Hans Theodor Eich, Michael Oertel · 2026 · Hematological Oncology
  51. Cardiometabolic vulnerability in cardio-oncology: mechanistic links, clinical implications, and emerging preventive strategies
    Jean Kim, Maishara Muquith, Le Huang, Alvin Chandra · 2026 · Current Opinion in Cardiology
  52. Subcutaneous Isatuximab by On-Body-Injector plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: ISASOCUT study
    Arthur Bobin, Cyrille Touzeau, Nicolas Branche et al. · 2026 · Research Square
  53. Targeting of CD28 and CD38 as a potential novel therapeutic strategy for peripheral T-cell lymphomas
    Aurélie Dupuy, Laura Pelletier, Asma Beldi‐Ferchiou, Elsa Poullot, Gamze Tari, Julie Naudet, François Lemonnier, Virginie Fataccioli, Barkha Gupta, Peter Kim et al. · 2026 · Scientific Reports
  54. Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study
    S. C. Kurniawan, Angela Hwang, Nicole Wong Doo et al. · 2026 · Asia-Pacific Journal of Clinical Oncology
  55. Front‐line systemic treatment outcomes in POEMS syndrome
    Oliver M Tomkins, Jahanzaib Khwaja, Shiwen Koay et al. · 2026 · British Journal of Haematology
  56. Efficacy and Safety of Anti-CD38 Antibody-Containing Triplet Regimens in Frail Patients with Multiple Myeloma
    Hirono Iriuchishima, Akio Saito, Masahiro Mihara, Shuhei Kanaya, Ryo Yoshizawa, Atsushi Isoda, Morio Matsumoto · 2026 · Cancers
  57. Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial
    Kenshi Suzuki, Morio Matsumoto, Hiroyuki Takamatsu et al. · 2026 · International Journal of Hematology
  58. FDA Approval of daratumumab and hyaluronidase-fihj plus vrd for the frontline treatment of newly diagnosed multiple myeloma
    Laiba Riaz, Wajeeha Komal, Rahimeen Qureshi · 2026 · Irish Journal of Medical Science (1971 -)
  59. Anti-CD38-based quadruplet versus triplet induction regimens in transplant-ineligible newly diagnosed multiple myeloma: a systematic review and meta-analysis
    Grace Lau, Madhu Bhargavi Chandra, Henri Fero, Fahad Alabbas · 2026 · International Journal of Hematology
  60. Lenalidomide Plus Dexamethasone as FIRST‐Line Therapy in Transplant‐Ineligible Patients With Multiple Myeloma: Final Results of the Prospective, Non‐Interventional Study FIRST ‐ NIS and Comparison With the FIRST Pivotal Phase III Clinical Trial
    Holger Nückel, Timo Behlendorf, H. Schulz, Matthias Bernd Schulze, C. Schardt, Tanja Medinger, Michael Koenigsmann, Tobias Nicolaas Dechow, Martin Indorf, D Bürkle et al. · 2026 · Cancer Medicine
  61. Développement et évaluation d'anticorps bispécifiques dans le traitement du Myélome multiple
    Maxime Fayon · 2019 · theses.fr (ABES)
  62. Apport de l’imagerie fonctionnelle par TEP dans la prise en charge diagnostique et thérapeutique du myélome multiple et comparaison à l’IRM de diffusion
    Charles Mesguich · 2020 · theses.fr (ABES)
  63. Etude de la kinase PIM2 dans la différenciation terminale normale et tumorale des lymphocytes B en plasmocytes
    Marion Haas · 2023 · theses.fr (ABES)
  64. A dexamethasone‐free daratumumab–ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018‐02 phase II study
    Arthur Bobin, Margaret Macro, Cyrille Touzeau et al. · 2026 · British Journal of Haematology
  65. Clinical Outcomes of Daratumumab-Containing Regimens in Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Sara O. Elgendy, Mohamed S. Imam, Amal Ali Alshehri, Wejdan Zaed Ali Alsufyani, Maha Albogami, Sumayyah Abdullah Saeed Almalki, Maya Nammas M. Alkhaldi, Majdolene Wael Abdulfattah Samarkandi, Demah Turki Yaqoub Alibrahim, Faten Ali Hefdhallah Hakami et al. · 2026 · BioMedInformatics
  66. Feasibility of post-induction consolidation with BCMA CAR-T cell therapy in newly diagnosed multiple myeloma not proceeding to ASCT: A preliminary case series
    Jiaying Wu, Rubing Zheng, Xi Ming · 2026 · Cell Transplantation
  67. Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS
    Sonja Zweegman, Thierry T.F. Facon, Vânia Hungria, Nizar Jacques Bahlis, Christopher Paul Venner, Marc Justin Braunstein, Luděk Pour, Josep Marti, Supratik Basu, Yael C. Cohen et al. · 2026 · Blood Advances
  68. Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma Across a Regional Academic–Community Network
    Poy P. Theprungsirikul, Amer Al-Musa, Noffar Bar, Sabrina L. Browning, Terri Parker, Natalia Neparidze · 2026 · Cancers
  69. Awareness and Utilization of the Revised Second International Staging System ( R2 ‐ ISS ) and 1q21 Gain/Amplification Testing: A Nationwide Web‐Based Survey of Hematologists in Japan
    Nami Tagami, Heigoroh Shirai, Ichiro Hanamura · 2026 · Cancer Medicine
  70. Knowledge, Awareness, and Practice Patterns of Nephrologists in the Diagnosis and Management of Multiple Myeloma (MIND-MM Study): A Cross-Sectional, Web-Based, CHERRIES-Compliant Survey with Position Statement from the Indian Myeloma Academic Groupe (IMAGe) and Indian Society of Nephrology (ISN)
    Uday Yanamandra, Raja Ramachandran, Vinay Sakhuja, Ranjith K. Nair, Vivekanand Jha, Shaji Kunnathu Kumar, Nelson Leung, Pankaj Malhotra · 2026 · Clinical Lymphoma Myeloma & Leukemia
  71. Anaemia in multiple myeloma: evolving insights into bone marrow microenvironment-driven pathogenesis and targeted management
    Li Pan, Hui Xie, Yanqiang Ji, Fusheng Zhang, Jie En Tan, Z Chen · 2026 · European journal of medical research
  72. Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients
    Huan Xie, M N Xiang, Meijuan Zhang · 2026 · Frontiers in Immunology
  73. Use of daratumumab in first-line therapy for multiple myeloma
    V. V. Voytsekhovskiy, T.V. Esenina, E. A. Filatova et al. · 2026 · Bulletin physiology and pathology of respiration
  74. Связь AL-амилоидоза и множественной миеломы: необходимость ранней диагностики и агрессивной терапии в современной клинической практике
    Е. В. Зуховицкая, В.Ю. Пинчук, И.А. Искров · 2026 · Гематология Трансфузиология Восточная Европа
  75. Multiple Myeloma and the Illusion of the Evidence Pyramid
    Fortunato Morabito, Enrica Antonia Martino, Antonella Bruzzese et al. · 2026 · European Journal Of Haematology
  76. Bridging Randomized Trial Efficacy and Real‐World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real‐World Evidence for Individualized Care
    Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Santino Caserta, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino et al. · 2026 · European Journal Of Haematology
  77. Multiples Myelom
    Maximilian Merz, H Goldschmidt · 2026 · Springer Reference Medizin
  78. POEMS Syndrome as a Mask of Multiple Myeloma: A Case Report with a Significant Response to Daratumumab Therapy
    Alvina Madieva, Azat Baglanovich Karabekov, Akbota Tursyn · 2026 · Oncology Nuclear Medicine and Transplantology
  79. Multimorbidity patterns and survival outcomes in older adults with multiple myeloma: findings from SEER-Medicare
    Atinuke G. Oyinbo, Maira A. Castañeda‐Avila, Jonggyu Baek · 2026 · Leukemia & lymphoma/Leukemia and lymphoma
  80. Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS
    Sonja Zweegman, Saad Z. Usmani, Vania Tietsche de Moraes Hungria et al. · 2026 · Leukemia
  81. Multiple Myeloma: 2026 Update on Diagnosis, Risk‐Stratification and Management
    S. Vincent Rajkumar · 2026 · American Journal of Hematology
  82. Integrating clinical and economic outcomes in the elderly myeloma management: a comparative cost-effectiveness analysis
    Antonio Giovanni Solimando, Vanessa Desantis, Lucia Di Marzo et al. · 2026 · Frontiers in Oncology
  83. Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis
    Thierry T.F. Facon, Shaji Kunnathu Kumar, Robert Zygmunt Orlowski, Nizar Jacques Bahlis, Philippe Moreau, Hartmut Goldschmidt, Supratik Basu, Cyrille Hulin, Sonja Zweegman, Katja Christina Weisel et al. · 2026 · Leukemia
  84. Cellular and molecular impacts of CELMoDs and IMiD on the induction of myeloid‐derived suppressor cells by myeloma cells
    Yui Niiyama‐Uchibori, Taku Tsukamoto, Yu Inoue, Shotaro Chinen, Takahisa Nakamura, Hiroaki Nagata, Haruya Okamoto, Takahiro Fujino, Shinsuke Mizutani, Yuji Shimura et al. · 2026 · British Journal of Haematology
  85. First-Line treatment for transplant-ineligible newly diagnosed multiple myeloma: a Bayesian network meta-analysis of efficacy, safety, and high-risk subgroups
    Dani Zhong, Hao Cheng, lin zeng, Chun Tian, Chunchun Liang, Hongyu Wei, Mengling Xu, Meili Pang, Qing Ke, Xiaohong Tan et al. · 2026 · Frontiers in Immunology
  86. Real World Data and Its Impact on the Management of Plasma Cell Dyscrasias
    Naveen G. Subramanian, Samuel M. Rubinstein · 2026 · Current Hematologic Malignancy Reports
  87. Refining the simplified frailty scale to improve the risk stratification of patients with multiple myeloma
    Yukiyasu Kato, Tomotaka Suzuki, Aki Kondo, Naohiro Matsunaga, Takaki Kikuchi, Takashi Kanamori, Takashi Yoshida, Satoshi Kayukawa, Yu Asao, Hiroki Yano et al. · 2026 · Journal of Geriatric Oncology
  88. EXABS-198-MM: Frailty in Multiple Myeloma: Implications Across the Treatment Landscape
    Hira S. Mian · 2026 · Clinical Lymphoma Myeloma & Leukemia
  89. Machine Learning and Molecular Modeling Reveal HDAC6 as a Key Target of Tanshinone IIA in Multiple Myeloma
    Jian Gao, Jiawen Chu, Pengpeng Li · 2026 · The Journal of Physical Chemistry B
  90. Cardiovascular disease and amyloidosis in phase III multiple myeloma trials: a systematic review of eligibility, screening and event reporting
    Oliver H Peck, Aimee McCoubrey, John Andrew Snowden, Ashutosh D. Wechalekar, Jennifer Travers, Jennifer Susan Lees, Mark Colquhoun Petrie, Ninian N. Lang · 2026 · Open Heart
  91. Diagnostic features and treatment approaches for AL amyloidosis: a literature review and clinical case report
    Yu. E. Ryabukhina, Pervin A. Zeynalova, Ахобеков Альберт Амалиевич, F. M. Abbasbeyli, Z. Z. Ivanova, М. М. Давыдов · 2026 · Oncohematology
  92. Beyond Remission: Risk-Adapted Maintenance and Mechanism-Guided Salvage After CAR T-Cell Therapy for Multiple Myeloma
    Shuai Su, Sijia Yan, Jiaying Wu, Yi Xiao · 2026 · Stem Cell Reviews and Reports
  93. Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma
    Wenwen Cheng, Silvia Gaggero, Lama Hasan Bou Issa, Aïcha Ouelkdite, Guillaume Escure, Adeline Cozzani, Yanick Tchantchou Njosse, Noémie Carlier, Emilie Wauquier, Gauthier Decool et al. · 2026 · Biomarker Research
  94. IFM 2026 Recommendations for First-line Treatment of Newly Diagnosed Multiple Myeloma
    Aurore Perrot, Salomon Manier, Cyrille Hulin, Hélène Demarquette, Arthur Bobin, Laurent Frenzel, Lionel Karlin, Olivier Decaux, Mohamad Mohty, Bertrand Arnulf et al. · 2026 · Clinical Lymphoma Myeloma & Leukemia
  95. Treatment Decisions in Multiple Myeloma
    Tarek H. Mouhieddine, Kenneth Carl Anderson · 2026 · New England Journal of Medicine
  96. Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making
    Abdul Hamid Bazarbachi, Suzanne Lentzsch, Thierry T.F. Facon, Jean‐Luc Harousseau, Mohamad Mohty · 2026 · Journal of Clinical Oncology
  97. Efficacy and safety of daratumumab-based quadruplet therapy vs non-daratumumab-based triplet therapy in newly diagnosed multiple myeloma patients: A GRADE assessed systematic review and meta-analysis of randomized controlled trials
    Muhammad Osama, Muhammad Haris Khan, Ammara Tahir et al. · 2026 · Therapeutic Advances in Hematology
  98. Myeloma‐Associated Sporadic Late‐Onset Nemaline Myopathy, Successfully Treated with Daratumumab Based Induction and Autologous Stem Cell Transplantation: A Case Report
    Kenji Moriwaki, Yawara Kawano, Makoto Nakajima · 2026 · eJHaem
  99. Additional file 3 of Prognostic and immune infiltration features of disulfidptosis-related subtypes in breast cancer
    Chen, Sheng, Li, Xiangrong, Wen Ao · 2024 · Figshare
  100. Additional file 4 of Prognostic and immune infiltration features of disulfidptosis-related subtypes in breast cancer
    Chen, Sheng, Li, Xiangrong, Wen Ao · 2024 · Figshare